The therapeutic options for castration-resistant prostate cancer (CRPC) remain limited. Here, the authors highlight the role of methionine adenosyltransferase 2a (MAT2A) in epigenetic reprogramming and suggest its therapeutic targeting in CRPC.
- Alessia Cacciatore
- Dheeraj Shinde
- Giuseppina M. Carbone